| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Lawrence Blonde, Vivian Fonsec. GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE REVIEW OF HOW TO WEIGH THE OPTIONS, SELECT THE RIGHT PATIENTS, AND MAXIMIZE BENEFITS. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2019-11-20. PMID:30084684. |
exciting new evidence continues to emerge, showing the utility of certain glp-1 receptor agonists to decrease incident cardiovascular (cv) outcomes, and to bolster glycemic control when combined with other antihyperglycemic therapies, including basal insulin. |
2019-11-20 |
2023-08-13 |
Not clear |
| Lawrence Blonde, Vivian Fonsec. GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE REVIEW OF HOW TO WEIGH THE OPTIONS, SELECT THE RIGHT PATIENTS, AND MAXIMIZE BENEFITS. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2019-11-20. PMID:30084684. |
the recent availability of fixed-ratio glp-1 receptor agonist and basal insulin coformulations-and a new, first-ever, indication for the use of a glp-1 receptor agonist (liraglutide) to reduce the risk of major adverse cv events (mace) in adults with t2d and established cardiovascular disease (cvd)-increase options for improved care. |
2019-11-20 |
2023-08-13 |
Not clear |
| Jennifer Clements, Katherine Moore, Kayce Sheal. Dulaglutide, a GLP-1 receptor agonist, for the treatment of type 2 diabetes. Expert review of endocrinology & metabolism. vol 10. issue 6. 2019-11-20. PMID:30289034. |
based on the most recent guidelines for t2dm, glp-1 receptor agonists can be prescribed as monotherapy or in combination with oral antidiabetic agents or insulin for the management of t2dm. |
2019-11-20 |
2023-08-13 |
Not clear |
| Sheila A Doggrel. Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY. Expert review of endocrinology & metabolism. vol 10. issue 3. 2019-11-20. PMID:30298769. |
advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly glp-1 receptor agonist, versus thrice-daily prandial insulin lispro. |
2019-11-20 |
2023-08-13 |
human |
| Srinivasan Vedantham, Anna-Kristina Kluever, Elisabeth Deind. Is there a Chance to Promote Arteriogenesis by DPP4 Inhibitors Even in Type 2 Diabetes? A Critical Review. Cells. vol 7. issue 10. 2019-11-20. PMID:30360455. |
gliptins are dipeptidyl-peptidase 4 (dpp4/cd26) inhibitors, which stabilize glucagon-like peptide-1 (glp-1), thereby increasing the bioavailability of insulin. |
2019-11-20 |
2023-08-13 |
Not clear |
| Vivian Fonseca, Ajay D Ra. DPP-4 inhibitors as a new target of action for Type 2 diabetes mellitus: a focus on vildagliptin. Expert review of endocrinology & metabolism. vol 2. issue 5. 2019-11-20. PMID:30736119. |
dpp-4 inhibitors delay the degradation of glp-1, in turn extending the action of insulin and suppressing the release of glucagon. |
2019-11-20 |
2023-08-13 |
Not clear |
| Vivian Fonseca, Ajay D Ra. DPP-4 inhibitors as a new target of action for Type 2 diabetes mellitus: a focus on vildagliptin. Expert review of endocrinology & metabolism. vol 2. issue 5. 2019-11-20. PMID:30736119. |
endogenous and exogenous glp-1 not only stimulates the release of insulin, but also reduces the secretion of glucagon. |
2019-11-20 |
2023-08-13 |
Not clear |
| Peixin Li, Zhijian Rao, Brenton Laing, Wyatt Paul Bunner, Taylor Landry, Amber Prete, Yuan Yuan, Zhong-Tao Zhang, Hu Huan. Vertical sleeve gastrectomy improves liver and hypothalamic functions in obese mice. The Journal of endocrinology. 2019-11-20. PMID:30875680. |
while serum active glp-1 level was increased, the active ghrelin and triglycerides levels were decreased along with improved insulin resistance in vsg group. |
2019-11-20 |
2023-08-13 |
mouse |
| Vivian A Fonseca, Matthew S Capehorn, Satish K Garg, Esteban Jódar Gimeno, Oluf Hoejbjerg Hansen, Anders Gaarsdal Holst, Gurudutt Nayak, Jochen Seufer. Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide. The Journal of clinical endocrinology and metabolism. 2019-11-20. PMID:30938762. |
semaglutide, a once-weekly glucagon-like peptide 1 (glp-1) analog approved for use in patients with type 2 diabetes (t2d), demonstrated superior body weight (bw) reductions and decreased insulin resistance (ir) vs comparators across the sustain 1-3 clinical trials. |
2019-11-20 |
2023-08-13 |
human |
| Andrea Tura, Giovanni Pacini, Yuchiro Yamada, Yutaka Seino, Bo Ahré. Glucagon and insulin secretion, insulin clearance, and fasting glucose in GIP receptor and GLP-1 receptor knockout mice. American journal of physiology. Regulatory, integrative and comparative physiology. vol 316. issue 1. 2019-11-19. PMID:30462524. |
glucagon and insulin secretion, insulin clearance, and fasting glucose in gip receptor and glp-1 receptor knockout mice. |
2019-11-19 |
2023-08-13 |
mouse |
| Andrea Tura, Giovanni Pacini, Yuchiro Yamada, Yutaka Seino, Bo Ahré. Glucagon and insulin secretion, insulin clearance, and fasting glucose in GIP receptor and GLP-1 receptor knockout mice. American journal of physiology. Regulatory, integrative and comparative physiology. vol 316. issue 1. 2019-11-19. PMID:30462524. |
it is not known whether gip receptor and glp-1 receptor knockout (ko) mice have perturbations in glucagon secretion or insulin clearance, and studies on impact on fasting glycemia have previously been inconsistent in these mice. |
2019-11-19 |
2023-08-13 |
mouse |
| Andrea Tura, Giovanni Pacini, Yuchiro Yamada, Yutaka Seino, Bo Ahré. Glucagon and insulin secretion, insulin clearance, and fasting glucose in GIP receptor and GLP-1 receptor knockout mice. American journal of physiology. Regulatory, integrative and comparative physiology. vol 316. issue 1. 2019-11-19. PMID:30462524. |
we therefore studied glucagon secretion after oral whey protein (60 mg) and intravenous arginine (6.25 mg), insulin clearance after intravenous glucose (0.35 g/kg) and fasting glucose, insulin, and glucagon levels after standardized 5-h fasting in female gip receptor and glp-1 receptor ko mice and their wild-type (wt) littermates. |
2019-11-19 |
2023-08-13 |
mouse |
| Andrea Tura, Giovanni Pacini, Yuchiro Yamada, Yutaka Seino, Bo Ahré. Glucagon and insulin secretion, insulin clearance, and fasting glucose in GIP receptor and GLP-1 receptor knockout mice. American journal of physiology. Regulatory, integrative and comparative physiology. vol 316. issue 1. 2019-11-19. PMID:30462524. |
furthermore, the intravenous glucose test revealed normal insulin clearance in both gip receptor and glp-1 receptor ko mice, whereas β-cell glucose sensitivity was enhanced in gip receptor ko mice and reduced in glp-1 receptor ko mice. |
2019-11-19 |
2023-08-13 |
mouse |
| Nathaniel J Hart, Craig Weber, Klearchos K Papas, Sean W Limesand, Josef Vagner, Ronald M Lync. Multivalent activation of GLP-1 and sulfonylurea receptors modulates β-cell second-messenger signaling and insulin secretion. American journal of physiology. Cell physiology. vol 316. issue 1. 2019-11-14. PMID:30404557. |
multivalent activation of glp-1 and sulfonylurea receptors modulates β-cell second-messenger signaling and insulin secretion. |
2019-11-14 |
2023-08-13 |
Not clear |
| Amornpan Lertrit, Sasinee Srimachai, Sunee Saetung, Suwannee Chanprasertyothin, La-Or Chailurkit, Chatvara Areevut, Pornalat Katekao, Boonsong Ongphiphadhanakul, Chutintorn Sriphrapradan. Effects of sucralose on insulin and glucagon-like peptide-1 secretion in healthy subjects: a randomized, double-blind, placebo-controlled trial. Nutrition (Burbank, Los Angeles County, Calif.). vol 55-56. 2019-11-04. PMID:30005329. |
this study aims to determine the effects of chronic exposure to sucralose on glycemic response, insulin secretion and sensitivity, and glucagon-like peptide-1 (glp-1) release in healthy subjects. |
2019-11-04 |
2023-08-13 |
human |
| Zheng Li, Chunxia Liu, Jianyong Yang, Jiaqi Zhou, Zhiwen Ye, Dazhi Feng, Na Yue, Jiayi Tong, Wenlong Huang, Hai Qia. Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold. European journal of medicinal chemistry. vol 179. 2019-11-04. PMID:31279294. |
moreover, cpu014 promotes insulin secretion in a glucose-dependent manner, while no glp-1 secretion has been enhanced. |
2019-11-04 |
2023-08-13 |
Not clear |
| Maarja Toots, Kadri Seppa, Toomas Jagomäe, Tuuliki Koppel, Maia Pallase, Indrek Heinla, Anton Terasmaa, Mario Plaas, Eero Vasa. Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome. Scientific reports. vol 8. issue 1. 2019-10-28. PMID:29976929. |
early chronic intervention with the glp-1 receptor agonist liraglutide starting before the onset of metabolic symptoms prevented the development of glucose intolerance, improved insulin and glucagon secretion control, reduced er stress and inflammation in langerhans islets in wfs1 mutant rats. |
2019-10-28 |
2023-08-13 |
human |
| Carolina B Ribeiro, Fernanda M Ramos, John A Manthey, Thais B Cesa. Effectiveness of Eriomin® in managing hyperglycemia and reversal of prediabetes condition: A double-blind, randomized, controlled study. Phytotherapy research : PTR. vol 33. issue 7. 2019-10-28. PMID:31183921. |
treatment with all doses of eriomin (200, 400, and 800 mg) had similar effects and altered significantly the following variables: blood glucose (-5%), insulin resistance (-7%), glucose intolerance (-7%), glycated hemoglobin (-2%), glucagon (-6.5%), c-peptide (-5%), hscrp (-12%), interleukin-6 (-13%), tnfα (-11%), lipid peroxidation (-17%), systolic blood pressure (-8%), glp-1 (+15%), adiponectin (+19%), and antioxidant capacity (+6%). |
2019-10-28 |
2023-08-13 |
Not clear |
| Katherine A Lyseng-Williamso. Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features. Clinical drug investigation. vol 39. issue 8. 2019-10-28. PMID:31317516. |
by stimulating glp-1 receptors, glp-1ras increase insulin secretion and suppress glucagon release in a glucose-dependent manner, thereby improving clinical and patient-reported outcomes related to glycaemic control and weight. |
2019-10-28 |
2023-08-13 |
Not clear |
| Manveen K Gupta, Neelakantan T Vasudeva. GPCRs and Insulin Receptor Signaling in Conversation: Novel Avenues for Drug Discovery. Current topics in medicinal chemistry. vol 19. issue 16. 2019-10-28. PMID:31512997. |
major treatment modalities for diabetes include the drugs from the class of sulfonyl urea, insulin, glp-1 agonists, sglt2 inhibitors, dpp-iv inhibitors and thiazolidinediones. |
2019-10-28 |
2023-08-13 |
Not clear |